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Microbiota, Inflammation, and 
Gut Barrier Dysfunction in HCC
Amit Kumar Ram, Gavin Wright  
and Balasubramaniyan Vairappan
Abstract
Hepatocellular carcinoma (HCC), which represents 90% of all primary liver can-
cers, is the fifth most common cancer and the third cause of cancer mortality rate. It 
is a complex disease with a poor prognosis. Incidence and mortality rates are increas-
ing in many geographical regions, indicating a need for better management strate-
gies. Chronic inflammation is the major driving factors for HCC development, which 
typically develops on the background of chronic liver disease (CLD). Currently, a 
large body of literature has focused on the key role of the gut-liver axis as the major 
pathophysiological mechanism of hepatic disease severity and HCC development. 
This chapter will describe the role of gut microbiota, inflammation, and intestinal 
barrier dysfunction-associated mechanism in the progression of HCC. In particular, 
enteric dysbiosis, tight junction, and inflammatory mediators in the pathogenesis of 
liver cancer will be discussed. Furthermore, this chapter will identify the possible 
potential therapeutic approach for the control of gut bacterial overgrowth, inflam-
mation and restoration of eubiosis, and tight junction integrity in HCC.
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1. Introduction
Hepatocellular carcinoma (HCC) is a heterogeneous type of tumor that is likely 
to develop on the background of an inflammatory milieu in patients with advanced 
liver disease. It is the third leading cause of cancer death globally and is more 
prevalent in men than in women [1]. Over the past two decades, there is increas-
ing evidence from studies suggesting a causal link between gut microbiota in the 
progression of HCC. Normal commensal gut microbiota acts as an important source 
of energy and is pivotal to host metabolism and innate immunity [2].  
Highlights
• Gut dysbiosis, inflammation, and increased intestinal permeability are synergistically contributed to 
the pathogenesis of hepatocellular carcinoma.
• Previous studies in animal models suggest that targeting the gut-liver axis can inhibit HCC 
development.
• Targeting the gut-liver axis with probiotics, antibiotics, FMT, TLR4 antagonists, FXR agonists, and 
natural compounds could be the promising strategies for HCC prevention.
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Not unsurprisingly therefore, alteration to gut microbial composition has been linked 
to the promotion of chronic inflammatory bowel disease (IBD) via local effects. 
However, activation of such inflammatory effects can have a broader response across 
all organ beds such as the liver, kidney, brain, heart, and the hematopoietic system 
and have been strongly associated with carcinogenesis [3]. Anatomical consider-
ations provide us with a logical understanding on why gut microbiosis may have such 
an impact on disease development, especially in the liver. Since the liver is anatomi-
cally connected to the intestine via the portal vein, it is the first organ to receive 
nutrient-rich blood and also the first target of gut microbiota. Furthermore, the liver 
can elicit an inflammatory response through microbe-associated molecular patterns 
(MAMPs) and pattern recognition receptors (PRRs). Though translocation of gut 
microbiota from the intestinal lumen to the systemic circulation is counterchecked 
by multilayer intestinal epithelium, any change in its integrity can initiate inflamma-
tion and contribute to fibrosis and thus chronic liver disease (CLD) progression and 
thus a precursor to HCC development, which is itself usually only seen in the context 
of cirrhosis, the most advanced form of CLD [4]. In this chapter, we summarize the 
available literature on the key role of gut microbiome in HCC pathogenesis and novel 
therapeutic approaches developed to target these processes.
2. Gut microbiota
The gut microbiota resides in the gastrointestinal (GI) tract. The human gut har-
bors complex and diverse microbial community of 100 trillion microorganisms with 
more than 2000 distinct species of bacteria, in addition to fungi protozoans and 
viruses. These microorganisms are collectively called gut microbiota, which com-
prises of commensals, beneficial microbiota, and opportunistic pathogens residing 
in what is a complex and dense microenvironment. Immediately after birth com-
mensal bacteria colonize the intestine and predominantly comprise Proteobacteria, 
Lactobacillus, and Actinobacteria, but as we mature into adults Bacteroidetes and 
Firmicutes species predominate [5]. The composition of microbiota also varies from 
the small intestine to the distal colon, due largely to the effects of nutrient availabil-
ity, intestinal pH, and motility. Moreover the overall composition of the microbial 
community in the gut is further individualized by any alteration in our diet, age, 
lifestyle, disease, and also medication exposure [6]. A symbiotic relationship exists 
between gut microbiota and the human host, which are critical to our maintenance 
of health. For example, gut microbiota are involved in the metabolism of bile 
acids, synthesis of vitamins, digestion of complex polysaccharides, and produc-
tion of short-chain fatty acids (SCFAs) [2]. SCFAs are a vital source of energy for 
enterocytes, which are integral in maintaining gut barrier integrity. In addition, gut 
microbiota are also involved in the development of local and innate immunity pro-
viding defense against not only the pathogenic invasion but also systemic infection 
[7]. Experimental studies from rodents and humans have demonstrated that the 
gut microbiota is involved in the progression of HCC by increasing LPS-mediated 
pro-inflammatory microenvironment in the liver.
3. Gut-liver axis
Gut microbiota are known to influence multiple extraintestinal organs; however 
the importance of the gut-liver axis has understandably received greater attention in 
recent years. The gut and liver share anatomy from the embryonic phase, with bidi-
rectional interaction through the portal vein. The symbiotic relationship between the 
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gut microbiota and the liver is modulated by the nutrition, immune, metabolic, and 
neuroendocrine crosstalk between them and thus shapes human health and disease 
[8]. Functionally, gut and liver coordination influences our physiology. The liver 
receives 70% of the blood supply from the gut via the portal circulation. The nutrient-
rich blood from the gut is effectively processed by the liver and delivered to systemic 
circulation for normal body growth. In turn, the liver synthesizes bile acids (BAs) and 
other mediators, like IgA, which influence intestinal microbial composition and barrier 
integrity, thereby maintaining intestinal homeostasis [8]. Bile acids are involved in 
energy homeostasis by regulating the metabolism of glucose and lipids and also help 
in conjugation and detoxification process as well as maintenance of intact intestinal 
epithelia. Bile acids also regulate microbial composition via antimicrobial peptides 
production; in turn, microbiota influences the bile acid pool in the intestine as they are 
involved in secondary bile acid production [9]. IgA secreted from the liver and intestine 
prevents growth and invasion of pathogenic bacteria to maintain normal gut-liver 
homeostasis [7]. In normal physiological conditions, translocation of gut bacteria 
and their metabolites is tightly regulated by the intestinal epithelial barrier, and if any 
reaches the liver, it is eliminated by hepatic Kupffer cells. Any breach in barrier integrity 
resulting from intestinal inflammation allows microbiota to pass through the portal vein 
to potentially trigger hepatic immune cells to enact an inflammatory response (from 
hepatic stellate cells and Kupffer cells), which may result in necrotic inflammation and 
hepatic fibrosis contributing to worsening fibrosis and thus liver disease progression 
[10]. Accumulating evidence suggests gut dysbiosis, bacterial endotoxin, and increased 
intestinal permeability are hallmark features of CLD and positively correlate with 
disease severity. These factors play a crucial role in the pathogenesis of not only CLD 
but have also been shown to promote HCC through various mechanisms (Figure 1).
Figure 1. 
An overview of homeostatic and impaired gut-liver axis in HCC progression. (A) In homeostatic condition 
gut lumen contains normal gut flora which is restricted by tightly closed intestinal epithelial cells to prevent 
its translocation to the liver. (B) Increased bacterial overgrowth in gut lumen and increased intestinal 
permeability promotes HCC progression through binding of LPS to toll-like receptor 4 (TLR4) which are 
present on Kupffer cells, hepatocytes, and HSC to elicit the release of pro-inflammatory cytokines and 
activation of proliferative and anti-apoptotic signals. Prebiotics, probiotics, synbiotics, FMT, and polyphenols 
can be used to restore eubiosis, while the use of antibiotics can potentially eliminate pathogenic bacteria and 
endotoxin release. FXR agonists can attenuate intestinal permeability and prevent bacterial translocation. 
TLR4 antagonists prevent binding of LPS to TLR4 and suppress cancer-promoting signals.
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4. Gut dysbiosis
Dysbiosis defines any change in the typical gut microbial composition found in 
health. Several lines of evidence suggest that gut bacterial dysbiosis is a pathogenic 
factor in the progression of HCC whatever the trigger for CLD (e.g., alcohol, non-
alcoholic steatohepatitis (NASH), viral hepatitis, etc.). The role of gut dysbiosis in 
the propagation of progressive CLD is likely triggered by the formation of microbial 
metabolites such as LPS, bacterial DNA, and deoxycholic acid, which causes chronic 
inflammation in the portal circulation and thus the liver. In cirrhotic patients 
overgrowth of the pathogenic bacteria such as Enterobacteriaceae, Veillonellaceae, 
and Streptococcaceae and decreased Lachnospiraceae have been observed to correlate 
with the child-turcotte-pugh (CTP) score, clinically used to assess the severity of 
cirrhosis [11]. Moreover, in cirrhotic patients studies have found an increase in both 
the oral and gut levels of the same microbial species suggesting invasion from the 
mouth to intestine [12]. It is therefore postulated oral bacterial overgrowth may 
have a profound effect on intestinal bacterial communities and thus CLD pathogen-
esis and HCC development. This concept is supported by a recent study that showed 
a high level of oral microbiota Oribacterium and Fusobacterium in HCC patients [13]. 
The alteration in gut microbiota composition in HCC is summarized in Table 1.
Microbial gene signatures that relate to energy production, nickel/iron trans-
port, and amino acid transport appear to be altered in HCC patients when com-
pared to healthy controls [13]. Moreover, when compared to cirrhotic patients, fecal 
samples from HCC patients have shown increased growth of phylum Actinobacteria 
and 13 genera including Gemmiger and Parabacteroides [14]. They also found a 
decrease in butyrate-producing bacteria and an increase in LPS-producing bacteria 
in HCC patients when compared to healthy controls [14]. A study conducted by 
Ponziani et al. in NAFLD-related HCC showed increased fecal Bacteroides and 
Ruminococcaceae, whereas reduced Akkermansia and Bifidobacterium were negatively 
correlated with intestinal inflammatory marker fecal calprotectin level [15]. This 
study also showed increased intestinal permeability in these patients accompanied 
by an increase in plasma level of IL8, IL13, CCL3, CCL4, and CCL5, showing the evi-
dence that alteration in gut microbiota profile is associated with systemic inflamma-
tion that may contribute to HCC pathogenesis [15]. In another study, E. coli growth 
in fecal samples was significantly elevated in HCC patients compared to matched 
cirrhotic patients [16]. Interestingly, inoculation of AFB1 and/or Helicobacter 
hepaticus in Helicobacter-free C3H/HeN mice was associated with HCC progression 
[17]. This observation may suggest that neither direct bacterial translocation nor 
hepatocyte injury is necessary for HCC development. In clinical studies utilizing 
liver HCC tumor biopsy tissue, some authors report the presence of Helicobacter ssp. 
DNA, whereas other investigators failed to correlate the presence of Helicobacter 
ssp. DNA with HCC progression [18]. In DEN-treated rats, fecal and cecal samples 
show an increase of pathogenic bacterial species like E. coli, Atopobium, Collinsella, 
Eggerthella, and Corynebacterium; in contrast there was a decline in the numbers of 
beneficial bacteria like Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. 
[19]. Although the exact mechanism by which gut microbiota promotes HCC has 
not been firmly established, studies in murine models indicated LPS-TLR4 axis plays 
a crucial role in the progression of HCC [19, 20]. Zhang et al. suggest that gut dys-
biosis merely promotes HCC by increasing LPS levels and that conversely probiotics 
may suppresses tumor growth [19]. Similarly, Dapito et al. propose that gut micro-
biota only has a role in the promotion of HCC rather than its initiation [20]. The 
ability of pathogenic bacteria to disrupt TJs protein thereby increasing intestinal 
permeability has also been postulated as another mechanism by which microbiota 
may promote CLD and HCC [21]. However further preclinical and clinical studies 
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are needed to establish the causal link between gut microbiota and HCC progression 
and to further delineate the molecular mechanisms involved.
5.  Inflammation as a key player: triggered by LPS-TLR4 mediated pathway
HCC is arising in an inflammatory environment of the CLD, and therefore, 
neutralizing inflammation with anti-inflammatory agents may reduce the incidence 
and recurrence of HCC. Much attention has been focused on the potential involve-
ment of the toll-like receptors (TLR) signaling pathway in the development of liver 
inflammation and associated HCC progression. Gut-derived endotoxin initiates the 
innate immune system such as TLRs, which recognize bacterial products and are 
predominantly expressed throughout the gut-liver axis. In addition, TLR4 plays a 
central role through LPS (a component of Gram-negative bacteria)-induced hepatic 
inflammation, while TLR 2 senses component of Gram-positive bacteria such as 
Authors Sample type Changes in fecal 
microbiota composition
Clinical implication in HCC
Ren et al. [14] Feces Klebsiella i • Increase in lipopolysaccharide-
producing bacteria promotes 
HCC progression
• Decrease in butyrate-producing 
bacteria promotes intestinal 
mucosal injury which contrib-
utes to HCC development
Ponziani et al. [15] Feces Bacteroides ↑
Ruminococcaceae ↑
Enterococcus ↑
Phascolarctobacterium ↑
Oscillospira ↑
Bifidobacterium ↓
Blautia ↓
• Increase in Gram-negative bac-
teria promotes HCC progression
• Decrease in beneficial bacteria 
was correlated with intestinal 
inflammation favoring local 
microenvironment for HCC 
development
Grat et al. [16] Feces Escherichia coli ↑ • Increase in pathogenic E. coli 
contributes to HCC progression
Huang et al. [18] HCC liver 
biopsy
Helicobacter pylori ↑ • Helicobacter linked to hepato-
carcinogenesis by colonizing 
the liver
Zhang et al. [19] Feces Escherichia coli ↑
Atopobium cluster ↓
Prevotella ↓
Bacteroides ↑
Lactobacillus spp. ↑
Bifidobacterium spp. ↑
Enterococcus spp. ↓
• Alteration in gut microbiota 
profile promoted tumor forma-
tion in DEN-induced HCC rats
Yoshimoto et al. [38] Feces Clostridium cluster XI and 
XIVa ↑
• Increase in deoxycholic acid 
-producing bacteria accelerated 
HCC progression in DMBA-
HFD-induced HCC rats
• Deoxycholic acid is a risk 
factor for obesity-induced HCC 
development
Table 1. 
Gut microbiota dysbiosis in HCC.
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peptidoglycan [22]. In this context, Yu et al. identified that increased activation of 
the TLR 4-LPS axis correlated with intestinal permeability in DEN-induced acute 
liver failure (ALF), which directly regulates pro-survival molecules and enhances 
hepatocyte proliferation [23]. Interestingly, in mice models the use of antibiotics 
and/or TLR4 genetic ablation prevented tumor growth and multiplicity [19, 23]. 
Dapito et al. showed a close link between gut microbiota and LPS-TLR 4 axis in 
HCC progression in a chimeric mice model [20]. This study also showed in DEN-
CCl4 treated mice (with histological CLD) that low-dose LPS treatment triggered 
TLR4 activation and increased rate of tumor formation, whereas gut sterilization 
prevented HCC progression rather than regression of the established tumor [20]. 
Taken together these studies would therefore suggest that gut microbiota may 
not have a role in HCC initiation but may instead have a tumor-promoting effect 
through TLRs signaling pathways [20].
In respect of HCC promotion, multiple downstream targets of the LPS-TLR4 
axis have been identified in both in vitro and in vivo studies. HSCs, Kupffer cells, 
and hepatocytes show TLR4 expression and thus are sensitive to LPS challenge [24]. 
Dapito et al. showed that TLR4 activation in HSCs, hepatocytes, and non-bone-
marrow-derived resident cells promotes hepatocarcinogenesis by upregulating 
epiregulin (hepatomitogen) and inhibiting cleaved caspase 3 via NF-κB activa-
tion [20]. Moreover, Yu et al. showed hepatic Kupffer cells as the chief target for 
LPS-induced TLR4 activation by increasing pro-inflammatory cytokines such as 
TNF-α and IL-6 production [23]. Similarly, in vitro studies have shown evidence 
of LPS-TLR4-promoted HCC cell proliferation via NF-κB, MAPK, and STAT3 
mediated signaling pathways [24]. LPS-TLR4 has also been shown to promote 
epithelial-to-mesenchymal transition (EMT) in HCC by upregulating NF-κB- and 
JNK/MAPK-mediated expression, while NF-κB and JNK/MAPK signaling blockade 
inhibited EMT occurrence [25]. Similarly, LPS-TLR4 axis is also known to enhance 
angiogenesis in HCC mice model via production of pro-angiogenic factors by HSCs 
in tumor stroma [26]. However further studies incorporating TLR4 deletion are 
needed to better understand its role in hepatocyte proliferation and distinguish 
paracrine signaling from HSCs and Kupffer cells in HCC progression.
6.  Intestinal epithelial barrier dysfunction: role of tight junction 
proteins
Commensals and opportunistic pathogens are kept in check within the intesti-
nal lumen by a single layer of intestinal epithelial cells (IEC) which spans almost 
400 m2 in surface area [27]. The gut barrier is highly dynamic in nature in which 
IEC is capable of self-renewal every 4–7 days with constant changes in intestinal 
luminal content. IEC are predominantly composed of absorptive enterocytes, 
which have metabolic and digestive functions. It also has secretory functions 
enacted by cell types such as enteroendocrine, goblet, and paneth cells which are 
specialized for maintaining digestive, immune, and epithelial barrier function [27]. 
Enteroendocrine cells connect the central and enteric neuroendocrine system via 
the secretion of various digestive hormones like gastrin, cholecystokinin, incretin, 
etc. The highly glycosylated mucins secreted by goblet cells form the first line of 
defense against microbial invasion and when compromised may predispose to 
disease as is evident in Mucin 2-deficient mice which are susceptible to colitis and 
inflammation-induced colorectal cancer [28, 29]. The intestinal barrier function 
is further strengthened by antimicrobial peptides (AMPs) including defensin, 
cathelicidin, and lysozyme [27]. These AMPs disrupt bacterial cell membranes and 
prevent adherence to gut mucosa.
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Apart from IEC, the gut barrier is primarily maintained by tight junction 
(TJs) components (e.g., claudin, occludin, zonula occludens, and other junctional 
adhesion molecules (JAMs)) preserving intact epithelia which in turn regulate the 
paracellular movement of solutes, water, and other nutrients while restricting the 
entry of bacteria from the lumen to systemic circulation [30]. The mechanism of 
increased intestinal permeability is poorly understood. Growing evidence sug-
gests that inflammation and TJ protein disruption are two of the key players driv-
ing increased intestinal permeability. In our previous study, we found increased 
systemic ZO-1 level in HCC patients reflecting increased intestinal permeability 
[31]. Moreover, plasma ZO-1 level was positively correlated with the inflamma-
tory marker hs-CRP and with disease severity, suggesting inflammation drives 
intestinal permeability associated with HCC progression [31]. Bacterial overgrowth 
leads to increased production of pro-inflammatory cytokines such as TNF-α, 
IL-6, and IL-1β, which is mainly mediated through the TLR4-NF-kB signaling 
pathway, thereby promoting intestinal inflammation and HCC progression [19]. 
These pro-inflammatory cytokines have a direct effect on TJ proteins like claudin 
and ZO-1, leading to enhance intestinal permeability [32]. Furthermore, in both 
in vivo and in vitro models, LPS dose dependently increases intestinal permeability 
via upregulating TLR4-mediated CD14 expression in enterocytes [33]. Similarly, 
NLRP6-deficient mice show altered microbiota and enhanced colonic inflammation 
through the chemokine (C-C motif) ligand CCL5 [34]. This results in increased 
intestinal permeability to microbial products and thus increases hepatic inflamma-
tion and progression from NAFLD to NASH [34]. Moreover, enteric pathogens such 
as Escherichia coli and Clostridium difficile are increased in CLD and are capable of 
increased intestinal permeability by modulating TJ integrity [11, 21].
Bile acids are another key player for maintaining gut barrier function by promot-
ing intestinal epithelial cell proliferation and microbiota composition [35]. There is 
clear evidence that bile acids have both direct antimicrobial effect and an indirect 
effect through FXR-induced AMPs and thus control growth and adhesion of intes-
tinal bacteria. In fact, decreased bile acids pool in the intestine is associated with 
bacterial overgrowth and inflammation [36]. The study by Kakiyama et al. showed 
that cirrhosis reduced bile acids entering the intestine causing bacterial dysbiosis 
by reducing beneficial bacteria such as Gram-positive Blautia and Ruminococcaceae 
and increasing pathogenic bacteria like Enterobacteriaceae [37]. In a NASH-induced 
CLD/HCC mouse model, increased Gram-positive Clostridium clusters (XI and 
XVIa) were positively correlated with increased serum deoxycholic acid (DCA) 
[38]. Notably, Clostridium clusters are capable of synthesis of secondary bile acid 
DCA via 7α-dehydroxylation of primary bile acids. DCA is a DNA-damaging agent 
and a known pro-carcinogen shown to affect various cancer signaling pathways. In 
this context, a study by Yoshimoto et al. revealed DCA activates a senescent-associ-
ated secretory phenotype in HSCs, thereby producing various pro-inflammatory 
and pro-tumorigenic factors promoting HCC development in mice, while antibiotic 
treatment and/or blocking DCA production prevented HCC development [38]. 
Similarly, in a HCC mouse model induced by steatohepatitis-inducing high-fat diet 
(STHD-01), increased hepatic and fecal bile acids concentrations were observed 
[39]. In this model, DCA activated mTOR and promoted HCC development. 
However, following antibiotic treatment, there was a decrease in HCC progression 
suggesting an interrelationship between BA metabolism, gut microbiota, and HCC 
development [39].
Bile acids maintain homeostatic IEC proliferation via EGFR- and FXR-
dependent pathways, which helps the continuous regeneration of enterocytes 
and maintain intact epithelia [40]. Several studies demonstrate that the intestinal 
bile acid pool also regulates TJ protein distribution and expression. In Caco-2 cell 
Liver Pathology
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monolayers, incubation with dihydroxy bile acids decreased transepithelial resis-
tance (TER) and was accompanied by increased phosphorylation and redistribution 
of occludin [41]. In human colonic biopsies, DCA induces Cr-EDTA permeability 
altering TER and increasing translocation of E. coli. Several in vivo studies have also 
elucidated the role of bile acids in the regulation of TJ permeability [42]. In HFD 
mice increased intestinal bile acid pool was associated with increased intestinal per-
meability with decreased expression of TJ proteins ZO-2 and JAM-A [43]. Similarly, 
in bile duct ligated (BDL) rats where intestinal BA delivery was prevented, there 
was increased bacterial translocation and increased intestinal permeability with 
decreased expression of claudin-1 and occludin. Conversely, the above effects were 
ameliorated by FXR activation [44]. These studies highlighted the protective role 
of FXR in the maintenance of intestinal barrier integrity; however, it is unclear 
whether these effects were from direct activation of FXR on TJ proteins or indirect 
effects from altered mucosal immune cells. In addition to FXR, another bile acid 
receptor TGR5 also modulates barrier permeability and TJ protein expression. In 
TGR5 null mice, increased intestinal permeability due to alteration of TJ protein 
expression develops colitis [45]. Therefore, the quantity and composition of BA 
pool in the intestine represent an important factor in the regulation of gut microbial 
community and gut barrier integrity.
7.  Therapeutic approach controlling gut microbiota, gut dysbiosis, and 
inflammation to prevent HCC
7.1 Prebiotics, probiotics, and synbiotics
Traditionally, HCC is cured based on the available treatment options such as 
surgical treatment, chemotherapy, and local ablation therapy; however, patients are 
facing many problems including the poor hepatic reserve [46]. Furthermore, the 
possible therapeutic interventions targeting the gut-liver axis in HCC are summa-
rized in Table 2.
Prebiotics are non-absorbant and nondigestible food ingredients which promote 
growth or activity of beneficial bacteria like Bifidobacteria and Lactobacilli and 
inhibit the growth of potentially pathogenic bacteria [47]. Currently, prebiotics 
like lactulose, lactitol, fructo-oligosaccharides, and galacto-oligosaccharides are 
commercially available [48]. Synthetic disaccharides like lactulose and lactitol are 
extensively used for the treatment of hepatic encephalopathy in CLD patients as 
ammonia detoxifying agents [48]. Also, these disaccharides are metabolized by 
colonic bacteria to produce lactic acid and acetic acid due to which pH in the gut 
lumen is decreased [49]. Low pH enhances the growth of non-urease-producing 
lactobacilli and inhibits pathogenic urease-producing bacteria [50]. Chen et al. 
showed that in chronic viral hepatitis patients, lactitol administration signifi-
cantly decreased plasma endotoxin levels and increased the growth of beneficial 
Lactobacilli and Bifidobacteria species [51]. In contrast, Bajaj et al. reported lactu-
lose administration in patients with HE did not improve dysbiosis and increased 
growth of Gram-negative bacteria such as Enterobacteriaceae and Bacteroidaceae 
[52]. This indicates the pattern of gut microbiota abundance is the major determi-
nants of disease severity [52]. In HCC patients administration of lactulose (30 mL/
day) for 14 days significantly reduced ALT and bilirubin levels, while antioxidant 
enzyme SOD, anti-inflammatory markers IFN-γ and IL-4, and blood cells CD4(+)/
CD8(+) were found to be increased suggesting its ability to reduce inflammation 
and restore oxidation/antioxidant system imbalance [53]. Similarly in partial 
hepatectomized rats, administration of lactulose induces liver regeneration by 
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Authors Intervention class Medication Desired effect in HCC
Zong et al. 
[53]
Prebiotics Lactulose • Lactulose treatment to HCC patients 
increased antioxidant enzymes and anti-
inflammatory markers while improving 
tumor immunity and overall prognosis
Zhang 
et al. [19]
Probiotics VSL#3 • VSL#3 treatment to DEN-induced 
HCC rats reduced tumor number and 
multiplicity by ameliorating hepatic and 
intestinal inflammation and improving 
intestinal permeability and restoring 
eubiosis
El-Nezami 
et al. [63]
Probiotics Lactobacillus 
rhamnosus LC 705 and 
Propionibacterium 
freudenreichii subsp. 
shermani
• Treatment to AFB1-induced HCC 
patients reduced aflatoxin-DNA adduct 
excretion in urine
Li et al. 
[46]
Probiotics Prohep • Treatment with Prohep to DEN-induced 
HCC mice reduced tumor size and 
angiogenic factors VEGFA and TEK
Kumar 
et al. [62]
Probiotics Combination of 
probiotic fermented 
milk and chlorophyllin
• Treatment to AFB1-induced HCC rats 
reduced DNA damage, oncogenic signal, 
and tumor incidence
Yoshimoto 
et al. [38]
Antibiotics 4Abx (ampicillin, 
metronidazole, 
vancomycin, 
neomycin)
• Treatment with 4Abx in DMBA-HFD-
induced HCC rats reduced tumor 
number and tumor size
Abdel-
Hamid 
et al. [67]
Antibiotics Clarithromycin and 
azithromycin
• Treatment to DEN-CCL4/acetylami-
nofluorene-induced HCC rats induced 
intrinsic and extrinsic apoptosis and 
inhibited HCC progression
Dapito 
et al. [20]
Antibiotics Rifaximin • Rifaximin treatment to DEN-CCL4 
induced HCC rats reduced tumor 
number
Nguyen 
et al. [93]
TLR4 antagonists TAK-242 • TAK-242 treatment to transgenic HCC 
mice reduced tumor burden and amelio-
rated hepatic steatosis and fibrosis
Nkontchou 
et al. [117]
Nonselective 
β-blockers
Propranolol • Long-term treatment with propranolol 
reduced HCC incidence in HCV-related 
cirrhosis patients
Chang 
et al. [118]
Nonselective 
β-blockers
Propranolol • Treatment with propranolol reduced 
mortality risk and improved survival in 
unresectable/metastatic HCC patients
Bishayee 
et al. [121]
Natural compound Resveratrol • Resveratrol treatment to DEN-induced 
HCC rats reduced hepatic nodules and 
prevented HCC progression
Ji et al. 
[124]
Natural compound Quercetin • Quercetin treatment to DEN-
acetylaminofluorene-induced HCC rats 
reduced number of nodules
Teng et al. 
[125]
Natural compound Curcumin • Treatment with curcumin to HBV-related 
transgenic HCC mice reduced hepatic 
nodules and suppressed HCC progression
Table 2. 
Therapeutic intervention targeting the gut-liver axis in HCC.
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inducing hydrogen and abrogating oxidative stress (heme oxygenase-1, SOD-2) 
and inflammation (IL-6 and TNF-α) [54]. Moreover, mixed diets of galacto-
oligosaccharides and fructo-oligosaccharides to infants were increased the growth 
of Bifidobacterium; however, this formulation has not been tried in patients with 
liver disease [55].
Probiotics are live microorganisms which when administered in adequate 
amounts confer a health benefit for the host [56]. Probiotic supplementation was 
also shown to restore intestinal dysbiosis in CLD patients [48]. Furthermore, mice 
treated with probiotic such as VSL#3 significantly reduces Clostridium spp. and 
modified gut microbiota [57]. In cirrhotic patients, VSL#3 supplementation for 
nearly 6 months was shown to reduce the risk of hospitalization and improved 
CTP and MELD score [58]. Similarly, in NASH-associated obese children, treat-
ment with VSL#3 over the period of 4 months reduces fatty liver and improved 
lipid profile and insulin sensitivity [59]. The other probiotics such as Lactobacillus 
salivarius LI01 and Pediococcus pentosaceus LI05 reduced inflammation, protected 
the intestinal barrier, prevented bacterial translocation, restored eubiosis, 
and attenuated hepatic fibrosis in CCl4-induced cirrhotic rats [60]. Similarly, 
Lactobacillus GG (LGG) supplemented with standard diet in cirrhosis patients 
show significantly reduced blood endotoxemia and TNF-α, thereby restor-
ing eubiosis [61]. However, in HCC, probiotic usage is meager, and only a few 
studies have identified the therapeutic potential. VSL#3 (contains three strains 
of Bifidobacteria, four strains of Lactobacilli, and one strain of Streptococcus 
thermophilus) treatment to DEN-induced rat hepatocarcinogenesis has shown to 
attenuate HCC progression, reduce tumor number and multiplicity, ameliorate 
hepatic and intestinal inflammation, and thus restore gut dysbiosis [19]. Li et al. 
identified that subcutaneous administration of Prohep (a novel probiotic mixture 
of Lactobacillus rhamnosus GG, Escherichia coli Nissle 1917, and heat-inactivated 
VSL#3) reduced the tumor size and HCC growth [46]. Prohep improves benefi-
cial bacteria such as Prevotella and Oscillibacter and control tissue inflammation 
as evidenced by decreased T helper 17 cells in the gut, thereby attenuating the 
progression of HCC [46]. Moreover, in aflatoxin B1-induced HCC rats, treatment 
with probiotic fermented milk and chlorophyllin significantly reduced tumor 
incidence by decreasing the expression of cyclin D1, bcl-2, and c-myc proto-
oncogenes [62]. Similarly, aflatoxin-induced HCC patients treated with dietary 
supplementation of probiotics (using viable Lactobacillus rhamnosus LC 705 and 
Propionibacterium freudenreichii subsp. shermani) decreased the urinary excretion 
of aflatoxin-DNA adduct (AFB-N7 guanine) and improved HCC [63]. Thus, pro-
biotic supplementation could be beneficial to cirrhotic patients with the potential 
to progress to HCC.
Synbiotics are combined form of prebiotics and probiotics, which contains four 
fermentable fibers (symbiotic 2000) and four freeze-dried non-urease-producing 
lactic acid bacteria. Synbiotic administration to cirrhotic patients results in 
decreased plasma endotoxin and ammonia levels and increased fecal Lactobacillus 
spp. [64]. Interestingly 50% of these patients have improved child-turcotte-
pugh score compared to placebo [64]. Moreover, in NAFLD patients synbiotic 
supplementation has shown to have beneficial effects by improving lipid profile, 
glucose homeostasis, hepatic marker enzymes, and inflammatory markers [65]. 
Synbiotic (FloraGuard) administration also has a protective role in alcohol-induced 
liver injury in rats [66]. In addition, the synbiotic treatment restored ethanol-
induced intestinal permeability and increased the growth of beneficial bacteria 
Bifidobacterium spp. and Lactobacillus spp. [66]. Currently, studies are lacking for 
the use of synbiotics in chronic liver diseases or HCC prevention.
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8. Antibiotics
Several studies have postulated that antibiotic treatment may cause gut microbi-
ota dysbiosis. It may represent effective strategies to prevent the tumor-promoting 
gut microbiota, its metabolites DCA, and pro-inflammatory signal inducer LPS 
which all have a role in the progression of CLD and HCC. In DEN-CCl4- and DMBA-
HFD-induced HCC mice model, the oral antibiotics ampicillin, metronidazole, neo-
mycin, and vancomycin significantly reduced the tumor number and size [20, 38]. 
In addition, this antibiotic combination also reduced the liver fibrosis and improved 
liver histology in cirrhosis. Moreover, the effectiveness of antibiotics administration 
was enhanced when given at late-stage HCC in mice rather than earlier stage [20]. 
In another study conducted in DEN-induced HCC rats, clarithromycin and azithro-
mycin suppressed HCC progression through extrinsic and intrinsic apoptotic path-
ways, whereas erythromycin aggravated HCC and did not show antitumorigenic 
effect [67]. Vancomycin is an antibiotic used to treat a bacterial infection, which 
effectively prevented the mouse model of HCC; however, long-term administration 
to CLD patients develops potential side effects [38]. Many studies have concluded 
that norfloxacin and rifaximin treatments to cirrhotic patients have beneficial 
effects [68]. In a double-blind placebo-controlled clinical trial, long-term oral 
administration of norfloxacin to cirrhotic patients markedly reduces Gram-negative 
bacteria in the fecal matters and lowers the spontaneous bacterial peritonitis (SBP) 
[69]. Furthermore, CCl4-induced cirrhotic animals showed decreased SBP and 
inflammation following norfloxacin treatment [70]. Norfloxacin was identified as 
a promising antibiotic in regulating gut microbiota overgrowth and prevention of 
BT in both cirrhotic humans and rodents; indeed its effect on HCC patients remains 
unidentified. Rifaximin is a broad spectrum oral antibiotic having potential bacte-
ricidal activity against aerobic and anaerobic Gram-negative bacteria [71]. It is an 
excellent choice of drug to cure HE in advanced cirrhotic patients [72]. The study 
conducted by Vlachogiannakos et al. showed treatment with rifaximin for 4 weeks 
significantly decreased portal pressure and LPS levels in decompensated cirrhotic 
patients [73]. Long-term treatment with rifaximin reduces SBP occurrence, variceal 
bleeding, HRS, and HE with an overall improvement in survival rate in cirrhotic 
patients [74]. Similarly, in murine DEN-CCl4-induced HCC mouse model, rifaximin 
treatment was shown to ameliorate HCC progression [20]. Although rifaximin is 
clinically used for prevention of HE and other complications in cirrhotic patients, 
its role in HCC prevention in humans is further warranted.
9. Fecal microbiota transplantation (FMT)
Fecal microbiota transplantation is currently being used for the treatment of 
Clostridium difficile infection [75]. The enteric dysbiosis was restored to normal gut 
flora following FMT from healthy donor to Clostridium difficile-infected patients 
[75]. Moreover, in mice with gut dysbiosis induced by antibiotics and chemo-
therapy, treatments were reversed by FMT [76]. In experimental cirrhosis with 
hepatic encephalopathy, FMT improves liver function and HE grade by limiting 
inflammation and improving tight junction integrity [77]. In this context, Bajaj 
et al. reported that FMT in cirrhotic patients with recurrent HE improves cogni-
tion, restores dysbiosis, and improves MELD score compared to standard care in 
those patients [78]. A number of clinical trials are ongoing in patients with NASH 
and cirrhosis for the efficacy of FMT [79, 80]. Vrieze et al. reported in patients 
with severe metabolic syndrome that treatment with FMT from a healthy donor 
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improves liver biochemistry, peripheral insulin resistance, and restoration of eubio-
sis [81]. Furthermore, in alcoholic hepatitis patients, FMT treatment significantly 
reduced liver disease severity and HE occurrence [82]. FMT recipients also showed 
an increase in beneficial bacteria like Actinobacteria and Bifidobacterium longum 
and decrease in Pseudomonas and E. coli with an increase in bile secretion [82]. 
Collectively these findings indicated that FMT may restore gut dysbiosis and reduce 
complications in cirrhotic patients and thus attenuate HCC development. However, 
scarce literature supporting the beneficial effect of FMT and long-term study is 
needed to prove permanent colonization in altered gut microbiota environment 
in cirrhotic patients. Moreover, there is a chance of inducing viral infection and 
transmission of other pathogens through FMT which may have deleterious effect 
and immunosuppression in advanced liver disease patients [83, 84].
10. TLR agonist or antagonist
Numerous studies have shown that LPS-TLR4 is a key inflammatory pathway 
in the progression of CLD and has a tumor-promoting effect on HCC [20, 23, 85]. 
Therefore blocking this pathway might represent a promising treatment approach 
in controlling cirrhosis and HCC progression. Several TLR4 antagonists have 
been developed toward controlling LPS-activated TLR4-mediated inflammatory 
responses which include polymyxin B [86], glycolipids interfering CD14-LPS 
interaction [87], eritoran [88], resatorvid (TAK242) [89], and thalidomide [90]. In 
BDL-induced cirrhotic rats, intravenous administration of TAK-242 significantly 
reduces plasma transaminases and inflammatory cytokines [91]. It also ameliorates 
acetaminophen-induced acute liver failure [92]. Similarly, in transgenic HCC mice 
(HepPten−), TAK-242 treatment for 28 days significantly reduced tumor burden 
and ameliorated HCC progression [93]. Eritoran tetrasodium protects against 
liver ischemia/reperfusion injury by inhibiting inflammatory response induced by 
high-mobility group box protein B1 (HMGB1) [94]. Similarly in D-galactosamine- 
and LPS-induced acute liver failure, treatment with eritoran significantly reduces 
inflammation and hepatic marker enzymes [95]. Eritoran treatment also decreases 
proliferation and induces apoptosis in tumor cells in a chemically induced mouse 
model of colorectal carcinoma [96]. Although resatorvid and eritoran showed 
the beneficial effect in improving the survival of murine sepsis model, it failed to 
do so in patients with severe sepsis [97]. Several TLRs have been upregulated in 
HCC [98]. In addition, TLRs are also abundantly expressed on immune cells which 
recognize various pathogens such as HBV which upon activation induces an innate 
immune response [99]. All the TLRs are activated by two independent pathways: 
MyD88-dependent (except TLR3) and MyD88-independent (TLR3 and TLR4) 
pathway [100]. Activation of TLR3-TRIF signaling pathway leads to apoptotic 
activity independently and, in turn, also activates IRF3 transcription factor to 
produce interferons [100]. TLR3 agonist BM-06 (synthetic dsRNA) significantly 
inhibited HCC cell proliferation, increased apoptosis, and decreased cell invasion 
and migration with increased antiviral IFN level [101]. Activation of TLR9 leads to 
phosphorylation of NF-κB with increased production of pro-inflammatory cyto-
kine TNF-α, IL-6, and IL-10 [102]. Mohamed et al. showed that inhibition of TLR7 
and TLR9 with antagonist IRS-954 or chloroquine significantly reduces HCC cell 
proliferation, angiogenesis with increased apoptosis [103]. This was further sup-
ported by tumor xenograft and DEN-induced rat HCC model in which chloroquine 
treatment reduces HCC incidence [103]. Although growing evidence shows TLRs as 
an important mediator of HCC progression, the molecular mechanism for disease 
progression is not completely understood. Therefore, further research needs to be 
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done for the use of TLR agonist or antagonist as a drug target for HCC prevention 
since TLRs are also involved in both cancer-promoting mechanism and immune-
modulator which is responsible for an innate immune response against tumor cells 
and HBV and HCV infection [99, 104–106].
11. Prokinetics
Bacterial overgrowth due to impaired gut motility has been reported in cirrhotic 
patients [107]. Cisapride, a prokinetic drug, has shown beneficial effects not only by 
regulating intestinal motility but also inhibiting bacterial overgrowth and prevent-
ing bacterial translocation in both rodent models and liver cirrhotic patients [108, 
109]. Cisapride in combination with norfloxacin significantly reduces the incidence 
of SBP in high-risk cirrhotic patients [110]. Although the mechanism of impaired 
gastrointestinal motility in cirrhotic patients is unclear, increased adrenergic activ-
ity may be responsible for the altered motility.
12. Nonselective beta-blockers (NSBB)
Nonselective β-blockers are prevalently used in decompensated chronic liver dis-
ease patients to reduce morbidity and mortality. It is used as bleeding prophylaxis in 
cirrhotic patients with esophageal varices. NSBB also antagonizes β-adrenoceptors. 
The β-adrenergic receptor pathway is involved in maintaining normal physiologi-
cal functions. The catecholamines such as epinephrine and norepinephrine are the 
key ligands for β-adrenoceptors (β1 and β2). Furthermore, increased expression of 
β-adrenoceptors was observed in HCC cell membranes compared to healthy liver 
cells; however, the mechanisms remain unclear [111]. Catecholamines exhibit pro-
carcinogenic effects in gastric, pancreatic, and breast cancer, which is antagonized 
by NSBB. Its beneficial effects to reduce the risk of HCC have also been identified 
by the very recent observational and experimental trials [112]. Moreover, in ovarian 
and breast cancer patients, NSBB treatment was shown to reduce cancer formation 
and growth. In cirrhotic patients, increased catecholamines results in disease sever-
ity, and thus, NSBB treatment may be potent to inhibit carcinogenesis in cirrhosis 
[113]. A recent study by Leithead et al. showed NSBB is safe and may confer benefit 
in patients with ascites complicating the end-stage liver disease [114]. In addition, 
Reiberger et al. observed that NSBB treatment ameliorates intestinal permeability 
and reduces BT in cirrhotic patients [115]. In a recent study, Wang et al. showed 
propranolol induces apoptosis and suppresses proliferation of liver cancer cells 
[116]. Of note, long-term treatment with propranolol in patients with HCV-related 
cirrhosis reduces the incidence of HCC [117]. Similarly, in patients with unresect-
able/metastatic HCC cohort, propranolol treatment significantly reduces mortality 
risk and improved overall survival suggesting β-blockers might be another thera-
peutic approach in HCC prevention [118].
13. Natural compounds
Treatment with natural compounds and food ingredients like polyphenols 
represents another therapeutic approach in the restoration of eubiosis, modula-
tion of gut microbiota, reduction of inflammation, prevention of cirrhosis, and 
thus the progression of HCC. Many experimental data have shown evidence that 
flavonoids are proficient to alter gut microbial composition and restoration of 
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eubiosis in chronic liver diseases. Proanthocyanidin improves beneficial micro-
biota Bacteroides such as Lactobacillus spp. and Bifidobacterium spp. composition 
and reduces intestinal inflammation and oxidative damage, thereby attenuating 
experimental colon cancer. Resveratrol, a flavonoid, is shown to modulate intesti-
nal microbiota with a profound increase in Bifidobacterium spp. and Lactobacillus 
spp. and reduce systemic and colonic inflammation in rats [119]. Resveratrol also 
shown to have anticancer activity in HCC cell lines; inhibit proliferation, viability, 
invasion, and metastasis; and induce apoptosis [120]. Its anticancer property was 
also studied in DEN-induced hepatocarcinogenesis [121]. We found resveratrol 
treatment to cirrhotic mice attenuated systemic inflammation and ammonia levels 
and altered neuronal TJ proteins, thereby preventing secondary complications such 
as HE in cirrhosis [122]. Quercetin, a bioactive flavonoid, was shown to inhibit 
human HCC cell proliferation, migration, and invasion and trigger apoptosis 
both in vivo and in vitro [123]. Its profound antitumor effect was also shown 
in xenograft and DEN-induced HCC rodent models [124]. Curcumin, a power-
ful antioxidant, has a wide range of bioactive properties. Previous studies have 
shown evidence that curcumin has HCC chemoprevention in preclinical models 
as well as patients with HCC [125, 126]. Moreover, nimbolide from the leaf of the 
neem tree (Azadirachta indica) is another potential natural compound having 
antioxidant, anti-inflammatory, antibacterial, antiviral, and anticancer properties 
[127]. In vitro study in HCC cell line (HepG2) shows that nimbolide induces cell 
apoptosis by abrogating NF-κB and Wnt signaling pathway [128]. Currently, our 
lab is focusing on anticancer effects of nimbolide and its molecular mechanisms in 
an experimental hepatocarcinogenesis. Of note, these natural compounds have a 
wide variety of biological activities on gut microbiota and may preserve gut barrier 
integrity, microbial metabolites, TJ integrity, and mucosal immunology. Indeed, 
further human studies are warranted to see the effect of natural compounds on gut 
microbial modulation and prevention of HCC.
14. Targeting gut epithelial barrier to prevent HCC
Gut epithelial barrier acts as a fence for translocation of gut microbiota and 
its metabolite into the systemic circulation which is the major driving factor for 
CLD progression and HCC development [129]. Therefore, primarily targeting 
or restoring the gut epithelial barrier is an interesting therapeutic approach in 
HCC pathogenesis. Compelling evidence has shown that targeting gut microbiota 
(restoring eubiosis) directly or receptor-mediated pharmacological intervention 
using TLR4 antagonist or FXR agonist might improve epithelial barrier function 
[130, 131]. FXR is a BA receptor which is widely expressed throughout the gut-liver 
axis. Decreased BA is associated with intestinal bacterial overgrowth, increased 
gut permeability, and bacterial translocation in rodents [38]. FXR controls hepatic 
inflammation, promotes liver regeneration, and suppresses HCC formation 
mainly through enterokine FGF19 [132]. FXR null mice have an intestinal barrier 
dysfunction and high occurrence of HCC, whereas reactivation of FXR inhibited 
HCC through FGF15-cyp7a1 axis [133]. In this context, FXR agonist obeticholic 
acid (OCA) prevents gut barrier dysfunction and BT in cholestatic rats [131]. 
Furthermore, in CCl4-induced cirrhotic rats, OCA treatment significantly reduces 
BT and inhibits intestinal inflammation by restoring intestinal TJ proteins such as 
ZO-1 and occludin and antimicrobial peptides [134]. OCA treatment also improves 
hepatic inflammation and decreased portal pressure in BDL cirrhotic rats [135]. 
Consequently, OCA treatment may prevent HCC by limiting intestinal inflamma-
tion and improving gut barrier dysfunction in advanced liver disease.
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Increased TNF-α production in mesenteric lymph nodes by monocyte is the 
major factor responsible for increased intestinal permeability in cirrhosis and HCC 
[19, 136]. TNF-α decreases ZO-1 expression through NF-κB and MLCK activation 
[137]. TNF-α also downregulated occludin expression in Caco-2 enterocyte by 
targeting PI3k/Akt signaling [138]. In BDL rats, treatment with infliximab (IFX, 
a monoclonal antibody against TNF) significantly reduced portal pressure and 
attenuated inflammation [139]. Therefore modulating intestinal TJs protein with 
anti-TNF-α therapy may restore intestinal integrity. However, due to the immuno-
suppressive activity of TNF inhibitors, it may lead to systemic infection in cirrhosis 
patients. Hence, detailed knowledge for local inhibition is required for improve-
ment in gut barrier dysfunction without affecting innate immune response.
Retinoic acid can modulate TJs proteins. In a mice model of colitis characterized by 
gut permeability, treatment with retinoic acid enhances barrier function by upregulat-
ing TJs proteins claudin-1, claudin-4, and ZO-1 [140]. However, the effect of retinoic 
acid in the preservation of intestinal integrity has not been tested in cirrhosis and 
HCC. Modulation of the epithelial barrier with probiotics seems to be beneficial. In this 
regard, Zhang et al. showed probiotics VSL#3 (combination of S. thermophilus, four 
Lactobacillus species, and three Bifidobacterium species) treatment restores intestinal 
permeability and dysbiosis and prevented HCC progression in rats [19]. Similarly, pro-
biotics like E. coli Nissle1971 (ECN) was also shown to enhance intestinal TJs integrity 
by upregulating ZO-1 expression in the mouse model of DSS-induced colitis [141].
In addition, treatment with red wine polyphenol promoted barrier function by 
significantly increasing mRNA expression of TJ proteins occludin, claudin-5, and 
ZO-1 in cytokine-stimulated HT-29 colon epithelial cells [142]. Resveratrol also pre-
serves TJ barrier integrity and diminishes intestinal permeability by upregulating 
occludin, ZO-1, and claudin-1expression and thus abrogating intestinal inflamma-
tion and oxidative stress both in vivo and in vitro [143]. Similarly in NAFLD mice 
model, treatment with resveratrol enhances barrier function by increasing mRNA 
expression of TJ proteins ZO-1, occludin, and claudin-1 in the intestinal mucosa 
[144]. Curcumin also modulates intestinal barrier integrity and attenuates paracel-
lular permeability and organization of TJs [145]. Thus, targeting TJ proteins, which 
maintain intact intestinal epithelia, is another area of therapeutic approach for the 
control of intestinal permeability in cirrhosis and HCC.
15. Clinical value
HCC is the end-stage liver disease, which mostly develops on the background 
of cirrhosis. As discussed above, the gut-liver axis plays a significant role in the 
progression of CLD and ultimately HCC and would be a potentially significant 
therapeutic target in the prevention of HCC. There have been several preclinical 
and human studies demonstrating an association between gut dysbiosis and HCC 
progression. However, from the animal studies, it is unclear whether gut microbiota 
initiates HCC or acts with other precipitating factors like chronic inflammation in 
the progression of HCC. Modulation of gut dysbiosis with prebiotics and probiotics, 
FMT, or preventing bacterial overgrowth with antibiotics may therefore prevent 
HCC. Moreover, in cirrhotic patients these interventions appeared to prevent 
secondary complications and improved survival. We may therefore speculate that 
the above interventions might prevent HCC development in high-risk cirrhotic 
patients. Moreover, we should consider trialing these therapies in HCC patients 
with unresectable tumors, which might improve survival time and secondary 
complications. Furthermore interventions that restore intestinal barrier integrity 
may prevent gut BT and may consider another line of therapy in HCC.
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16. Conclusion
In conclusion, there is growing evidence to suggest gut microbiota may play a 
significant role in the progression of CLD and thus HCC, which is likely to involve 
multiple pathways ranging from gut dysbiosis, endotoxemia, inflammation, loss 
of TJ integrity, and intestinal permeability. It is therefore suggested that the use of 
agents that have the potential to target microbial dysbiosis and restore intestinal 
epithelial barrier integrity may prevent bacterial translocation and ultimately delay 
HCC progression. However, whether bacterial overgrowth and/or intestinal perme-
ability act independently or synergistically as causal pathogenic factors to influence 
the inflammatory milieu so closely associated with HCC progression remains 
unclear. Further research is therefore warranted to better understand the molecular 
pathways involved and guide the development of novel therapeutic interventions 
that can be taken to clinical trial to limit CLD/HCC progression through the target-
ing of dysbiosis and its effect on inflammation and intestinal permeability.
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